Long-term results of XXXX for advanced @entity1893 .

@entity1 @entity5 @entity1442 @entity1893 @entity258 @entity1349
Sixty-eight @entity1 received fractionated @entity258 ( @entity258 ) as treatment for @entity1893 ( @entity1893 ) at the Rotterdamsch Radio-Therapeutisch Instituut (RRTI) in the period 1973-1979. Ninety percent (61/68) of these @entity1 had @entity1442 (Stage III + IV). According to current @entity5 grade classifications, 34 @entity1 had low grade @entity1893 , 10 intermediate, and 19 high grade. In 5 cases no exact grading was possible. @entity258 was given 3 times a week, midline dose 0.1 Gy, using 6 or 25 MeV photons to a mean total dose of 1.78 Gy. Initial response rate for low, intermediate, and high grade @entity1893 was resp. 84, 42, and 40%. The main prognostic factor for survival and @entity1349 ( @entity1349 ) was @entity5 grade. Probability of uncorrected survival at 10 years for low, intermediate, and high grade was resp. 34, 0 and 0%. Probability of @entity1349 at 10 years was resp. 19, 0, and 0%. Neither stage nor sex had any influence on survival. Age was reversely correlated with survival, but was not correlated with @entity1349 . Influence of prior therapy (18 @entity1 ) on survival and @entity1349 was separately analyzed. Neither survival nor @entity1349 of unfavorable @entity1893 (high and intermediate grade) was influenced. On the other hand @entity1 with a favorable @entity1893 (low grade) had a significantly (p less than 0.05) better @entity1349 if they received @entity258 as initial treatment, but survival was not significantly influenced. @entity1349 at 5 and 10 years of @entity1 who received @entity258 as first treatment was respectively 32% and 27%. No treatment related complications were noted. Subsequent chemotherapy in case of relapse was not hampered by previous @entity258 . The high response rate and extended @entity1349 , without maintenance therapy, makes @entity258 a preferable first line treatment for @entity1 with advanced stage low grade @entity1893 .
